{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:35:59Z","timestamp":1794540959870,"version":"4.9.1"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1038\/s41582-023-00811-4","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:23:25Z","timestamp":1684455805000},"page":"363-370","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Mechanisms underlying phenotypic variation in neurogenetic disorders"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5874-9204","authenticated-orcid":false,"given":"Jean-Marc","family":"Burgunder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"key":"811_CR1","doi-asserted-by":"publisher","first-page":"775330","DOI":"10.3389\/fgeed.2021.775330","volume":"3","author":"BL da Costa","year":"2021","unstructured":"da Costa, B. L., Levi, S. R., Eulau, E., Tsai, Y. T. & Quinn, P. M. J. Prime editing for inherited retinal diseases. Front. Genome Ed. 3, 775330 (2021).","journal-title":"Front. Genome Ed."},{"key":"811_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/mdc3.13163","volume":"8","author":"R Gannamani","year":"2021","unstructured":"Gannamani, R., van der Veen, S., van Egmond, M., de Koning, T. J. & Tijssen, M. A. J. Challenges in clinicogenetic correlations: one phenotype \u2014 many genes. Mov. Disord. Clin. Pract. 8, 311\u2013321 (2021).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"811_CR3","doi-asserted-by":"publisher","first-page":"639994","DOI":"10.3389\/fneur.2021.639994","volume":"12","author":"E Indelicato","year":"2021","unstructured":"Indelicato, E. & Boesch, S. From genotype to phenotype: expanding the clinical spectrum of CACNA1A variants in the era of next generation sequencing. Front. Neurol. 12, 639994 (2021).","journal-title":"Front. Neurol."},{"key":"811_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s12551-013-0126-y","volume":"6","author":"OD Uchitel","year":"2014","unstructured":"Uchitel, O. D., Gonzalez Inchauspe, C. & Di Guilmi, M. N. Calcium channels and synaptic transmission in familial hemiplegic migraine type 1 animal models. Biophys. Rev. 6, 15\u201326 (2014).","journal-title":"Biophys. Rev."},{"key":"811_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/ana.20169","volume":"56","author":"SD Spacey","year":"2004","unstructured":"Spacey, S. D., Hildebrand, M. E., Materek, L. A., Bird, T. D. & Snutch, T. P. Functional implications of a novel EA2 mutation in the P\/Q-type calcium channel. Ann. Neurol. 56, 213\u2013220 (2004).","journal-title":"Ann. Neurol."},{"key":"811_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/ng0197-62","volume":"15","author":"O Zhuchenko","year":"1997","unstructured":"Zhuchenko, O. et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat. Genet. 15, 62\u201369 (1997).","journal-title":"Nat. Genet."},{"key":"811_CR7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.cell.2013.05.059","volume":"154","author":"X Du","year":"2013","unstructured":"Du, X. et al. Second cistron in CACNA1A gene encodes a transcription factor mediating cerebellar development and SCA6. Cell 154, 118\u2013133 (2013).","journal-title":"Cell"},{"key":"811_CR8","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1002\/mds.28753","volume":"36","author":"A Balck","year":"2021","unstructured":"Balck, A. et al. Genotype-phenotype relations in primary familial brain calcification: systematic MDSGene review. Mov. Disord. 36, 2468\u20132480 (2021).","journal-title":"Mov. Disord."},{"key":"811_CR9","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3390\/genes13060963","volume":"13","author":"G Pfeffer","year":"2022","unstructured":"Pfeffer, G. et al. Multisystem proteinopathy due to VCP mutations: a review of clinical heterogeneity and genetic diagnosis. Genes 13, 963 (2022).","journal-title":"Genes"},{"key":"811_CR10","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.bbadis.2008.09.003","volume":"1782","author":"VE Kimonis","year":"2008","unstructured":"Kimonis, V. E., Fulchiero, E., Vesa, J. & Watts, G. VCP disease associated with myopathy, Paget disease of bone and frontotemporal dementia: review of a unique disorder. Biochim. Biophys. Acta 1782, 744\u2013748 (2008).","journal-title":"Biochim. Biophys. Acta"},{"key":"811_CR11","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1006\/bbrc.1994.2855","volume":"205","author":"J Berger","year":"1994","unstructured":"Berger, J., Molzer, B., Fae, I. & Bernheimer, H. X-linked adrenoleukodystrophy (ALD): a novel mutation of the ALD gene in 6 members of a family presenting with 5 different phenotypes. Biochem. Biophys. Res. Commun. 205, 1638\u20131643 (1994).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"811_CR12","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/mds.26651","volume":"31","author":"CM Lill","year":"2016","unstructured":"Lill, C. M. et al. Launching the movement disorders society genetic mutation database (MDSGene). Mov. Disord. 31, 607\u2013609 (2016).","journal-title":"Mov. Disord."},{"key":"811_CR13","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/mds.28485","volume":"36","author":"LM Lange","year":"2021","unstructured":"Lange, L. M. et al. Genotype-phenotype relations for isolated dystonia genes: MDSGene systematic review. Mov. Disord. 36, 1086\u20131103 (2021).","journal-title":"Mov. Disord."},{"key":"811_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41582-021-00595-5","volume":"18","author":"RA Hickman","year":"2022","unstructured":"Hickman, R. A., O\u2019Shea, S. A., Mehler, M. F. & Chung, W. K. Neurogenetic disorders across the lifespan: from aberrant development to degeneration. Nat. Rev. Neurol. 18, 117\u2013124 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"811_CR15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/mdc3.13165","volume":"8","author":"F Magrinelli","year":"2021","unstructured":"Magrinelli, F., Balint, B. & Bhatia, K. P. Challenges in clinicogenetic correlations: one gene \u2014 many phenotypes. Mov. Disord. Clin. Pract. 8, 299\u2013310 (2021).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"811_CR16","first-page":"1161","volume":"97","author":"AA Forder","year":"2007","unstructured":"Forder, A. A. A brief history of infection control \u2014 past and present. S. Afr. Med. J. 97, 1161\u20131164 (2007).","journal-title":"S. Afr. Med. J."},{"key":"811_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.22694","volume":"35","author":"T Syeda","year":"2021","unstructured":"Syeda, T. & Cannon, J. R. Environmental exposures and the etiopathogenesis of Alzheimer\u2019s disease: the potential role of BACE1 as a critical neurotoxic target. J. Biochem. Mol. Toxicol. 35, e22694 (2021).","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"811_CR18","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.3390\/ijms21072316","volume":"21","author":"B Peng","year":"2020","unstructured":"Peng, B. et al. Role of alcohol drinking in Alzheimer\u2019s disease, Parkinson\u2019s disease, and amyotrophic lateral sclerosis. Int. J. Mol. Sci. 21, 2316 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"811_CR19","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41586-021-04064-3","volume":"600","author":"SE Graham","year":"2021","unstructured":"Graham, S. E. et al. The power of genetic diversity in genome-wide association studies of lipids. Nature 600, 675\u2013679 (2021).","journal-title":"Nature"},{"key":"811_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JAD-220025","volume":"89","author":"K Clark","year":"2022","unstructured":"Clark, K., Leung, Y. Y., Lee, W. P., Voight, B. & Wang, L. S. Polygenic risk scores in Alzheimer\u2019s disease genetics: methodology, applications, inclusion, and diversity. J. Alzheimers Dis. 89, 1\u201312 (2022).","journal-title":"J. Alzheimers Dis."},{"issue":"Suppl. 1","key":"811_CR21","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1002\/mds.22721","volume":"25","author":"CM Tanner","year":"2010","unstructured":"Tanner, C. M. Advances in environmental epidemiology. Mov. Disord. 25 (Suppl. 1), S58\u2013S62 (2010).","journal-title":"Mov. Disord."},{"key":"811_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1515\/reveh-2021-0111","volume":"38","author":"T Chambers-Richards","year":"2021","unstructured":"Chambers-Richards, T., Su, Y., Chireh, B. & D\u2019Arcy, C. Exposure to toxic occupations and their association with Parkinson\u2019s disease: a systematic review with meta-analysis. Rev. Environ. Health 38, 65\u201383 (2021).","journal-title":"Rev. Environ. Health"},{"key":"811_CR23","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/mds.28902","volume":"37","author":"C Domenighetti","year":"2022","unstructured":"Domenighetti, C. et al. Dairy intake and Parkinson\u2019s disease: a Mendelian randomization study. Mov. Disord. 37, 857\u2013864 (2022).","journal-title":"Mov. Disord."},{"key":"811_CR24","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3390\/ijms22031045","volume":"22","author":"VG Chittoor-Vinod","year":"2021","unstructured":"Chittoor-Vinod, V. G., Nichols, R. J. & Schule, B. Genetic and environmental factors influence the pleomorphy of LRRK2 parkinsonism. Int. J. Mol. Sci. 22, 1045 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"811_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41572-021-00267-0","volume":"7","author":"FJ van Spronsen","year":"2021","unstructured":"van Spronsen, F. J. et al. Phenylketonuria. Nat. Rev. Dis. Primers\u00a07, 36 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"811_CR26","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00415-019-09608-2","volume":"267","author":"P Jaulent","year":"2020","unstructured":"Jaulent, P. et al. Neurological manifestations in adults with phenylketonuria: new cases and review of the literature. J. Neurol. 267, 531\u2013542 (2020).","journal-title":"J. Neurol."},{"key":"811_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/BF00692698","volume":"58","author":"ML Bauman","year":"1982","unstructured":"Bauman, M. L. & Kemper, T. L. Morphologic and histoanatomic observations of the brain in untreated human phenylketonuria. Acta Neuropathol. 58, 55\u201363 (1982).","journal-title":"Acta Neuropathol."},{"key":"811_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1086\/431216","volume":"77","author":"WQ Zeng","year":"2005","unstructured":"Zeng, W. Q. et al. Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3. Am. J. Hum. Genet. 77, 16\u201326 (2005).","journal-title":"Am. J. Hum. Genet."},{"key":"811_CR29","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0925-4439(01)00073-4","volume":"1537","author":"A Rajgopal","year":"2001","unstructured":"Rajgopal, A., Edmondnson, A., Goldman, I. D. & Zhao, R. SLC19A3 encodes a second thiamine transporter ThTr2. Biochim. Biophys. Acta 1537, 175\u2013178 (2001).","journal-title":"Biochim. Biophys. Acta"},{"key":"811_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1055\/s-0037-1607191","volume":"49","author":"M Alfadhel","year":"2018","unstructured":"Alfadhel, M. & Tabarki, B. SLC19A3 gene defects sorting the phenotype and acronyms: review. Neuropediatrics 49, 83\u201392 (2018).","journal-title":"Neuropediatrics"},{"key":"811_CR31","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/brain\/121.7.1267","volume":"121","author":"PT Ozand","year":"1998","unstructured":"Ozand, P. T. et al. Biotin-responsive basal ganglia disease: a novel entity. Brain 121, 1267\u20131279 (1998).","journal-title":"Brain"},{"key":"811_CR32","doi-asserted-by":"publisher","first-page":"683255","DOI":"10.3389\/fgene.2021.683255","volume":"12","author":"J Wang","year":"2021","unstructured":"Wang, J. et al. Report of the largest Chinese cohort with SLC19A3 gene defect and literature review. Front. Genet. 12, 683255 (2021).","journal-title":"Front. Genet."},{"key":"811_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-83","volume":"8","author":"M Alfadhel","year":"2013","unstructured":"Alfadhel, M. et al. Biotin-responsive basal ganglia disease should be renamed biotin-thiamine-responsive basal ganglia disease: a retrospective review of the clinical, radiological and molecular findings of 18 new cases. Orphanet J. Rare Dis. 8, 83 (2013).","journal-title":"Orphanet J. Rare Dis."},{"key":"811_CR34","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/bpa.12117","volume":"24","author":"A Schanzer","year":"2014","unstructured":"Schanzer, A. et al. Stress-induced upregulation of SLC19A3 is impaired in biotin-thiamine-responsive basal ganglia disease. Brain Pathol. 24, 270\u2013279 (2014).","journal-title":"Brain Pathol."},{"key":"811_CR35","doi-asserted-by":"publisher","first-page":"2329048X1877321","DOI":"10.1177\/2329048X18773218","volume":"5","author":"MA Alabdulqader","year":"2018","unstructured":"Alabdulqader, M. A. & Al Hajjaj, S. Biotin-thiamine-responsive basal ganglia disease: case report and follow-up of a patient with poor compliance. Child Neurol. Open 5, 2329048X18773218 (2018).","journal-title":"Child Neurol. Open"},{"key":"811_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/mds.27140","volume":"33","author":"HA Jinnah","year":"2018","unstructured":"Jinnah, H. A. et al. Treatable inherited rare movement disorders. Mov. Disord. 33, 21\u201335 (2018).","journal-title":"Mov. Disord."},{"key":"811_CR37","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12311-013-0531-6","volume":"13","author":"W Ilg","year":"2014","unstructured":"Ilg, W. et al. Consensus paper: management of degenerative cerebellar disorders. Cerebellum 13, 248\u2013268 (2014).","journal-title":"Cerebellum"},{"key":"811_CR38","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1007\/s00415-021-10897-9","volume":"269","author":"MP Hommersom","year":"2022","unstructured":"Hommersom, M. P. et al. The complexities of CACNA1A in clinical neurogenetics. J. Neurol. 269, 3094\u20133108 (2022).","journal-title":"J. Neurol."},{"key":"811_CR39","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1136\/jnnp.2009.177279","volume":"80","author":"AH Stam","year":"2009","unstructured":"Stam, A. H. et al. Early seizures and cerebral oedema after trivial head trauma associated with the CACNA1A S218L mutation. J. Neurol. Neurosurg. Psychiatry 80, 1125\u20131129 (2009).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"811_CR40","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S1474-4422(14)70011-0","volume":"13","author":"EL Heinzen","year":"2014","unstructured":"Heinzen, E. L. et al. Distinct neurological disorders with ATP1A3 mutations. Lancet Neurol. 13, 503\u2013514 (2014).","journal-title":"Lancet Neurol."},{"key":"811_CR41","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1002\/cne.24924","volume":"528","author":"K Murata","year":"2020","unstructured":"Murata, K. et al. Region- and neuronal-subtype-specific expression of Na,K-ATPase alpha and beta subunit isoforms in the mouse brain. J. Comp. Neurol. 528, 2654\u20132678 (2020).","journal-title":"J. Comp. Neurol."},{"key":"811_CR42","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/mds.28954","volume":"37","author":"J Prasuhn","year":"2022","unstructured":"Prasuhn, J. et al. In vivo brain sodium disequilibrium in ATP1A3-related rapid-onset dystonia-parkinsonism. Mov. Disord. 37, 877\u2013879 (2022).","journal-title":"Mov. Disord."},{"key":"811_CR43","doi-asserted-by":"publisher","first-page":"100019","DOI":"10.1074\/jbc.RA120.015271","volume":"296","author":"E Arystarkhova","year":"2021","unstructured":"Arystarkhova, E., Ozelius, L. J., Brashear, A. & Sweadner, K. J. Misfolding, altered membrane distributions, and the unfolded protein response contribute to pathogenicity differences in Na,K-ATPase ATP1A3 mutations. J. Biol. Chem. 296, 100019 (2021).","journal-title":"J. Biol. Chem."},{"key":"811_CR44","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/dmcn.12927","volume":"57","author":"R Dard","year":"2015","unstructured":"Dard, R. et al. Relapsing encephalopathy with cerebellar ataxia related to an ATP1A3 mutation. Dev. Med. Child Neurol. 57, 1183\u20131186 (2015).","journal-title":"Dev. Med. Child Neurol."},{"key":"811_CR45","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1093\/brain\/awab052","volume":"144","author":"A Vetro","year":"2021","unstructured":"Vetro, A. et al. ATP1A2- and ATP1A3-associated early profound epileptic encephalopathy and polymicrogyria. Brain 144, 1435\u20131450 (2021).","journal-title":"Brain"},{"key":"811_CR46","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000466","volume":"6","author":"L Prange","year":"2020","unstructured":"Prange, L. et al. D-DEMO, a distinct phenotype caused by ATP1A3 mutations. Neurol. Genet. 6, e466 (2020).","journal-title":"Neurol. Genet."},{"key":"811_CR47","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1212\/WNL.48.4.845","volume":"48","author":"MS van der Knaap","year":"1997","unstructured":"van der Knaap, M. S. et al. A new leukoencephalopathy with vanishing white matter. Neurology 48, 845\u2013855 (1997).","journal-title":"Neurology"},{"key":"811_CR48","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/ana.25287","volume":"84","author":"EMC Hamilton","year":"2018","unstructured":"Hamilton, E. M. C. et al. Natural history of vanishing white matter. Ann. Neurol. 84, 274\u2013288 (2018).","journal-title":"Ann. Neurol."},{"key":"811_CR49","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/ng764","volume":"29","author":"PA Leegwater","year":"2001","unstructured":"Leegwater, P. A. et al. Subunits of the translation initiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter. Nat. Genet. 29, 383\u2013388 (2001).","journal-title":"Nat. Genet."},{"key":"811_CR50","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.clineuro.2008.08.003","volume":"110","author":"N Damon-Perriere","year":"2008","unstructured":"Damon-Perriere, N. et al. Intra-familial phenotypic heterogeneity in adult onset vanishing white matter disease. Clin. Neurol. Neurosurg. 110, 1068\u20131071 (2008).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"811_CR51","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1055\/s-0032-1307456","volume":"43","author":"HD van der Lei","year":"2012","unstructured":"van der Lei, H. D. et al. Characteristics of early MRI in children and adolescents with vanishing white matter. Neuropediatrics 43, 22\u201326 (2012).","journal-title":"Neuropediatrics"},{"key":"811_CR52","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00234-022-03097-3","volume":"65","author":"MD Stellingwerff","year":"2023","unstructured":"Stellingwerff, M. D., van de Wiel, M. A. & van der Knaap, M. S. Radiological correlates of episodes of acute decline in the leukodystrophy vanishing white matter. Neuroradiology 65, 855\u2013863 (2023).","journal-title":"Neuroradiology"},{"key":"811_CR53","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1261\/rna.066563.118","volume":"24","author":"SL Moon","year":"2018","unstructured":"Moon, S. L. & Parker, R. EIF2B2 mutations in vanishing white matter disease hypersuppress translation and delay recovery during the integrated stress response. RNA 24, 841\u2013852 (2018).","journal-title":"RNA"},{"key":"811_CR54","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.56319","volume":"9","author":"MD Keefe","year":"2020","unstructured":"Keefe, M. D. et al. Vanishing white matter disease expression of truncated EIF2B5 activates induced stress response. eLife 9, e56319 (2020).","journal-title":"eLife"},{"key":"811_CR55","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.32733","volume":"7","author":"YL Wong","year":"2018","unstructured":"Wong, Y. L. et al. The small molecule ISRIB rescues the stability and activity of vanishing white matter disease eIF2B mutant complexes. eLife 7, e32733 (2018).","journal-title":"eLife"},{"key":"811_CR56","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00415-012-6765-2","volume":"260","author":"D Martino","year":"2013","unstructured":"Martino, D. et al. Extragenetic factors and clinical penetrance of DYT1 dystonia: an exploratory study. J. Neurol. 260, 1081\u20131086 (2013).","journal-title":"J. Neurol."},{"key":"811_CR57","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1002\/mds.21747","volume":"22","author":"C Natasa","year":"2007","unstructured":"Natasa, C., Petrovic, I., Klein, C. & Kostic, V. S. Delayed-onset dystonia due to perinatal asphyxia: a prospective study. Mov. Disord. 22, 2426\u20132429 (2007).","journal-title":"Mov. Disord."},{"key":"811_CR58","doi-asserted-by":"publisher","first-page":"105337","DOI":"10.1016\/j.nbd.2021.105337","volume":"154","author":"S Knorr","year":"2021","unstructured":"Knorr, S. et al. The evolution of dystonia-like movements in TOR1A rats after transient nerve injury is accompanied by dopaminergic dysregulation and abnormal oscillatory activity of a central motor network. Neurobiol. Dis. 154, 105337 (2021).","journal-title":"Neurobiol. Dis."},{"key":"811_CR59","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1007\/s13311-019-00823-3","volume":"16","author":"LM Ellerby","year":"2019","unstructured":"Ellerby, L. M. Repeat expansion disorders: mechanisms and therapeutics. Neurotherapeutics 16, 924\u2013927 (2019).","journal-title":"Neurotherapeutics"},{"key":"811_CR60","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00294-018-0865-1","volume":"65","author":"V Mosbach","year":"2019","unstructured":"Mosbach, V., Poggi, L. & Richard, G. F. Trinucleotide repeat instability during double-strand break repair: from mechanisms to gene therapy. Curr. Genet. 65, 17\u201328 (2019).","journal-title":"Curr. Genet."},{"key":"811_CR61","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","volume":"25","author":"P McColgan","year":"2018","unstructured":"McColgan, P. & Tabrizi, S. J. Huntington\u2019s disease: a clinical review. Eur. J. Neurol. 25, 24\u201334 (2018).","journal-title":"Eur. J. Neurol."},{"key":"811_CR62","first-page":"971","volume":"26","author":"No authors listed.","year":"1993","unstructured":"No authors listed. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group. Cell 26, 971\u2013983 (1993).","journal-title":"Cell"},{"key":"811_CR63","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/ajmg.a.33911","volume":"155A","author":"G Nicolas","year":"2011","unstructured":"Nicolas, G. et al. Juvenile Huntington disease in an 18-month-old boy revealed by global developmental delay and reduced cerebellar volume. Am. J. Med. Genet. A 155A, 815\u2013818 (2011).","journal-title":"Am. J. Med. Genet. A"},{"key":"811_CR64","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/j.1532-5415.2012.03912.x","volume":"60","author":"R Lefaucheur","year":"2012","unstructured":"Lefaucheur, R. et al. Chorea in an 83-year-old woman: don\u2019t forget Huntington\u2019s disease. J. Am. Geriatr. Soc. 60, 983\u2013984 (2012).","journal-title":"J. Am. Geriatr. Soc."},{"key":"811_CR65","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/ng0893-387","volume":"4","author":"M Duyao","year":"1993","unstructured":"Duyao, M. et al. Trinucleotide repeat length instability and age of onset in Huntington\u2019s disease. Nat. Genet. 4, 387\u2013392 (1993).","journal-title":"Nat. Genet."},{"key":"811_CR66","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/ene.12366","volume":"21","author":"H Jiang","year":"2014","unstructured":"Jiang, H. et al. Huntingtin gene CAG repeat numbers in Chinese patients with Huntington\u2019s disease and controls. Eur. J. Neurol. 21, 637\u2013642 (2014).","journal-title":"Eur. J. Neurol."},{"key":"811_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2014.146","volume":"16","author":"L Bean","year":"2014","unstructured":"Bean, L. & Bayrak-Toydemir, P. American College of Medical Genetics and Genomics Standards and Guidelines for Clinical Genetics Laboratories, 2014 edition: technical standards and guidelines for Huntington disease. Genet. Med. 16, e2 (2014).","journal-title":"Genet. Med."},{"key":"811_CR68","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.conb.2021.07.001","volume":"72","author":"EL Bunting","year":"2022","unstructured":"Bunting, E. L., Hamilton, J. & Tabrizi, S. J. Polyglutamine diseases. Curr. Opin. Neurobiol. 72, 39\u201347 (2022).","journal-title":"Curr. Opin. Neurobiol."},{"key":"811_CR69","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3233\/JHD-200429","volume":"10","author":"DG Monckton","year":"2021","unstructured":"Monckton, D. G. The contribution of somatic expansion of the CAG repeat to symptomatic development in Huntington\u2019s disease: a historical perspective. J. Huntingt. Dis. 10, 7\u201333 (2021).","journal-title":"J. Huntingt. Dis."},{"key":"811_CR70","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/hmg\/6.2.301","volume":"6","author":"SS Chong","year":"1997","unstructured":"Chong, S. S. et al. Contribution of DNA sequence and CAG size to mutation frequencies of intermediate alleles for Huntington disease: evidence from single sperm analyses. Hum. Mol. Genet. 6, 301\u2013309 (1997).","journal-title":"Hum. Mol. Genet."},{"key":"811_CR71","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/ajmg.a.20190","volume":"119A","author":"L Djousse","year":"2003","unstructured":"Djousse, L. et al. Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. Am. J. Med. Genet. A 119A, 279\u2013282 (2003).","journal-title":"Am. J. Med. Genet. A"},{"key":"811_CR72","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1007\/s00415-015-7900-7","volume":"262","author":"D Liu","year":"2015","unstructured":"Liu, D. et al. Motor onset and diagnosis in Huntington disease using the diagnostic confidence level. J. Neurol. 262, 2691\u20132698 (2015).","journal-title":"J. Neurol."},{"key":"811_CR73","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.cell.2019.06.036","volume":"178","author":"GH Consortium","year":"2019","unstructured":"Consortium, G. H. CAG repeat not polyglutamine length determines timing of Huntington\u2019s disease onset. Cell 178, 887\u2013900 (2019).","journal-title":"Cell"},{"key":"811_CR74","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41580-021-00382-6","volume":"22","author":"I Malik","year":"2021","unstructured":"Malik, I., Kelley, C. P., Wang, E. T. & Todd, P. K. Molecular mechanisms underlying nucleotide repeat expansion disorders. Nat. Rev. Mol. Cell. Biol. 22, 589\u2013607 (2021).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"811_CR75","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","volume":"380","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi, S. J. et al. Targeting huntingtin expression in patients with Huntington\u2019s disease. N. Engl. J. Med. 380, 2307\u20132316 (2019).","journal-title":"N. Engl. J. Med."},{"key":"811_CR76","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","volume":"101","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi, S. J., Ghosh, R. & Leavitt, B. R. Huntingtin lowering strategies for disease modification in Huntington\u2019s disease. Neuron 101, 801\u2013819 (2019).","journal-title":"Neuron"},{"key":"811_CR77","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","volume":"21","author":"SJ Tabrizi","year":"2022","unstructured":"Tabrizi, S. J. et al. Potential disease-modifying therapies for Huntington\u2019s disease: lessons learned and future opportunities. Lancet Neurol. 21, 645\u2013658 (2022).","journal-title":"Lancet Neurol."},{"key":"811_CR78","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3390\/pharmaceutics14081708","volume":"14","author":"J Helm","year":"2022","unstructured":"Helm, J., Schols, L. & Hauser, S. Towards personalized allele-specific antisense oligonucleotide therapies for toxic gain-of-function neurodegenerative diseases. Pharmaceutics 14, 1708 (2022).","journal-title":"Pharmaceutics"},{"key":"811_CR79","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10048-013-0365-x","volume":"14","author":"L Arning","year":"2013","unstructured":"Arning, L. & Epplen, J. T. Genetic modifiers in Huntington\u2019s disease: fiction or fact? Neurogenetics 14, 171\u2013172 (2013).","journal-title":"Neurogenetics"},{"key":"811_CR80","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3233\/JHD-200427","volume":"10","author":"EP Hong","year":"2021","unstructured":"Hong, E. P. et al. Huntington\u2019s disease pathogenesis: two sequential components. J. Huntingt. Dis. 10, 35\u201351 (2021).","journal-title":"J. Huntingt. Dis."},{"key":"811_CR81","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/S1474-4422(17)30161-8","volume":"16","author":"DJH Moss","year":"2017","unstructured":"Moss, D. J. H. et al. Identification of genetic variants associated with Huntington\u2019s disease progression: a genome-wide association study. Lancet Neurol. 16, 701\u2013711 (2017).","journal-title":"Lancet Neurol."},{"key":"811_CR82","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1093\/brain\/awz115","volume":"142","author":"M Flower","year":"2019","unstructured":"Flower, M. et al. MSH3 modifies somatic instability and disease severity in Huntington\u2019s and myotonic dystrophy type 1. Brain 142, 1876\u20131886 (2019).","journal-title":"Brain"},{"key":"811_CR83","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/mds.28565","volume":"36","author":"G Di Lazzaro","year":"2021","unstructured":"Di Lazzaro, G. et al. X-linked parkinsonism: phenotypic and genetic heterogeneity. Mov. Disord. 36, 1511\u20131525 (2021).","journal-title":"Mov. Disord."},{"key":"811_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23491-4","volume":"12","author":"BH Laabs","year":"2021","unstructured":"Laabs, B. H. et al. Identifying genetic modifiers of age-associated penetrance in X-linked dystonia-parkinsonism. Nat. Commun. 12, 3216 (2021).","journal-title":"Nat. Commun."},{"key":"811_CR85","doi-asserted-by":"publisher","first-page":"690899","DOI":"10.3389\/fmolb.2021.690899","volume":"8","author":"LEO Elsayed","year":"2021","unstructured":"Elsayed, L. E. O., Eltazi, I. Z., Ahmed, A. E. & Stevanin, G. Insights into clinical, genetic, and pathological aspects of hereditary spastic paraplegias: a comprehensive overview. Front. Mol. Biosci. 8, 690899 (2021).","journal-title":"Front. Mol. Biosci."},{"key":"811_CR86","first-page":"1043","volume":"128","author":"J von Fellenberg","year":"1998","unstructured":"von Fellenberg, J. et al. Clinical and molecular genetic analysis of 4 Swiss families with the pure form of hereditary spastic spinal paralysis. Schweiz. Med. Wochenschr. 128, 1043\u20131050 (1998).","journal-title":"Schweiz. Med. Wochenschr."},{"key":"811_CR87","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/15472","volume":"23","author":"J Hazan","year":"1999","unstructured":"Hazan, J. et al. Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat. Genet. 23, 296\u2013303 (1999).","journal-title":"Nat. Genet."},{"key":"811_CR88","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1093\/brain\/awy034","volume":"141","author":"T Newton","year":"2018","unstructured":"Newton, T. et al. Mechanistic basis of an epistatic interaction reducing age at onset in hereditary spastic paraplegia. Brain 141, 1286\u20131299 (2018).","journal-title":"Brain"},{"key":"811_CR89","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/bfgp\/els017","volume":"11","author":"P Ernst","year":"2012","unstructured":"Ernst, P. & Vakoc, C. R. WRAD: enabler of the SET1-family of H3K4 methyltransferases. Brief. Funct. Genomics 11, 217\u2013226 (2012).","journal-title":"Brief. Funct. Genomics"},{"key":"811_CR90","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/ajmg.b.32806","volume":"183","author":"IS Piras","year":"2020","unstructured":"Piras, I. S. et al. Huntingtin gene CAG repeat size affects autism risk: family-based and case-control association study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 183, 341\u2013351 (2020).","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"811_CR91","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1093\/brain\/awu174","volume":"137","author":"S Tezenas du Montcel","year":"2014","unstructured":"Tezenas du Montcel, S. et al. Modulation of the age at onset in spinocerebellar ataxia by CAG tracts in various genes. Brain 137, 2444\u20132455 (2014).","journal-title":"Brain"},{"key":"811_CR92","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/S1474-4422(16)30193-4","volume":"15","author":"NS Ryan","year":"2016","unstructured":"Ryan, N. S. et al. Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer\u2019s disease: a case series. Lancet Neurol. 15, 1326\u20131335 (2016).","journal-title":"Lancet Neurol."},{"key":"811_CR93","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00401-020-02249-0","volume":"141","author":"D Sepulveda-Falla","year":"2021","unstructured":"Sepulveda-Falla, D. et al. A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer\u2019s disease. Acta Neuropathol. 141, 217\u2013233 (2021).","journal-title":"Acta Neuropathol."},{"key":"811_CR94","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/mds.28874","volume":"37","author":"A Weissbach","year":"2022","unstructured":"Weissbach, A. et al. Relationship of genotype, phenotype, and treatment in dopa-responsive dystonia: MDSGene review. Mov. Disord. 37, 237\u2013252 (2022).","journal-title":"Mov. Disord."},{"key":"811_CR95","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1212\/WNL.50.4.1015","volume":"50","author":"Y Furukawa","year":"1998","unstructured":"Furukawa, Y. et al. Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia. Neurology 50, 1015\u20131020 (1998).","journal-title":"Neurology"},{"key":"811_CR96","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1046\/j.1471-4159.1999.0720757.x","volume":"72","author":"M Shimoji","year":"1999","unstructured":"Shimoji, M., Hirayama, K., Hyland, K. & Kapatos, G. GTP cyclohydrolase I gene expression in the brains of male and female hph-1 mice. J. Neurochem. 72, 757\u2013764 (1999).","journal-title":"J. Neurochem."},{"key":"811_CR97","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s00415-019-09633-1","volume":"268","author":"M Erfanian Omidvar","year":"2021","unstructured":"Erfanian Omidvar, M. et al. Genotype-phenotype associations in hereditary spastic paraplegia: a systematic review and meta-analysis on 13,570 patients. J. Neurol. 268, 2065\u20132082 (2021).","journal-title":"J. Neurol."},{"key":"811_CR98","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.parkreldis.2020.02.004","volume":"72","author":"SR Gan","year":"2020","unstructured":"Gan, S. R. et al. The impact of ethnicity on the clinical presentations of spinocerebellar ataxia type 3. Parkinsonism Relat. Disord. 72, 37\u201343 (2020).","journal-title":"Parkinsonism Relat. Disord."},{"key":"811_CR99","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1212\/WNL.0000000000000675","volume":"83","author":"F Hentati","year":"2014","unstructured":"Hentati, F. et al. LRRK2 parkinsonism in Tunisia and Norway: a comparative analysis of disease penetrance. Neurology 83, 568\u2013569 (2014).","journal-title":"Neurology"},{"key":"811_CR100","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3389\/fnmol.2018.00292","volume":"11","author":"I Lacal","year":"2018","unstructured":"Lacal, I. & Ventura, R. Epigenetic inheritance: concepts, mechanisms and perspectives. Front. Mol. Neurosci. 11, 292 (2018).","journal-title":"Front. Mol. Neurosci."},{"key":"811_CR101","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1007\/s12035-021-02391-0","volume":"58","author":"A Cazurro-Gutierrez","year":"2021","unstructured":"Cazurro-Gutierrez, A. et al. \u03b5-Sarcoglycan: unraveling the myoclonus-dystonia gene. Mol. Neurobiol. 58, 3938\u20133952 (2021).","journal-title":"Mol. Neurobiol."},{"key":"811_CR102","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/sj.ejhg.5200938","volume":"11","author":"M Grabowski","year":"2003","unstructured":"Grabowski, M. et al. The epsilon-sarcoglycan gene (SGCE), mutated in myoclonus-dystonia syndrome, is maternally imprinted. Eur. J. Hum. Genet. 11, 138\u2013144 (2003).","journal-title":"Eur. J. Hum. Genet."},{"key":"811_CR103","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1128\/MCB.20.9.3308-3315.2000","volume":"20","author":"G Piras","year":"2000","unstructured":"Piras, G. et al. Zac1 (Lot1), a potential tumor suppressor gene, and the gene for epsilon-sarcoglycan are maternally imprinted genes: identification by a subtractive screen of novel uniparental fibroblast lines. Mol. Cell Biol. 20, 3308\u20133315 (2000).","journal-title":"Mol. Cell Biol."},{"key":"811_CR104","doi-asserted-by":"publisher","first-page":"105074","DOI":"10.1016\/j.neuint.2021.105074","volume":"148","author":"JW Hyeon","year":"2021","unstructured":"Hyeon, J. W., Kim, A. H. & Yano, H. Epigenetic regulation in Huntington\u2019s disease. Neurochem. Int. 148, 105074 (2021).","journal-title":"Neurochem. Int."},{"key":"811_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18255-5","volume":"11","author":"AT Lu","year":"2020","unstructured":"Lu, A. T. et al. DNA methylation study of Huntington\u2019s disease and motor progression in patients and in animal models. Nat. Commun. 11, 4529 (2020).","journal-title":"Nat. Commun."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00811-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00811-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00811-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T12:03:14Z","timestamp":1685966594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00811-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":105,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["811"],"URL":"https:\/\/doi.org\/10.1038\/s41582-023-00811-4","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]},"assertion":[{"value":"12 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}